These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11784132)

  • 1. Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation.
    Tselios T; Apostolopoulos V; Daliani I; Deraos S; Grdadolnik S; Mavromoustakos T; Melachrinou M; Thymianou S; Probert L; Mouzaki A; Matsoukas J
    J Med Chem; 2002 Jan; 45(2):275-83. PubMed ID: 11784132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides.
    Tselios T; Daliani I; Probert L; Deraos S; Matsoukas E; Roy S; Pires J; Moore G; Matsoukas J
    Bioorg Med Chem; 2000 Aug; 8(8):1903-9. PubMed ID: 11003134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cyclic Altered Peptide Analogue Based on Myelin Basic Protein 87-99 Provides Lasting Prophylactic and Therapeutic Protection Against Acute Experimental Autoimmune Encephalomyelitis.
    Emmanouil M; Tseveleki V; Triantafyllakou I; Nteli A; Tselios T; Probert L
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.
    Matsoukas J; Apostolopoulos V; Kalbacher H; Papini AM; Tselios T; Chatzantoni K; Biagioli T; Lolli F; Deraos S; Papathanassopoulos P; Troganis A; Mantzourani E; Mavromoustakos T; Mouzaki A
    J Med Chem; 2005 Mar; 48(5):1470-80. PubMed ID: 15743189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85.
    Tselios T; Daliani I; Deraos S; Thymianou S; Matsoukas E; Troganis A; Gerothanassis I; Mouzaki A; Mavromoustakos T; Probert L; Matsoukas J
    Bioorg Med Chem Lett; 2000 Dec; 10(24):2713-7. PubMed ID: 11133075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis.
    Deraos G; Rodi M; Kalbacher H; Chatzantoni K; Karagiannis F; Synodinos L; Plotas P; Papalois A; Dimisianos N; Papathanasopoulos P; Gatos D; Tselios T; Apostolopoulos V; Mouzaki A; Matsoukas J
    Eur J Med Chem; 2015 Aug; 101():13-23. PubMed ID: 26112377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis.
    Tselios T; Probert L; Daliani I; Matsoukas E; Troganis A; Gerothanassis IP; Mavromoustakos T; Moore GJ; Matsoukas JM
    J Med Chem; 1999 Apr; 42(7):1170-7. PubMed ID: 10197961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design and synthesis of altered peptide ligands based on human myelin oligodendrocyte glycoprotein 35-55 epitope: inhibition of chronic experimental autoimmune encephalomyelitis in mice.
    Tselios T; Aggelidakis M; Tapeinou A; Tseveleki V; Kanistras I; Gatos D; Matsoukas J
    Molecules; 2014 Nov; 19(11):17968-84. PubMed ID: 25375337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg91, Ala96] MBP87-99.
    Mantzourani ED; Tselios TV; Grdadolnik SG; Brancale A; Platts JA; Matsoukas JM; Mavromoustakos TM
    J Mol Graph Model; 2006 Sep; 25(1):17-29. PubMed ID: 16310386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of experimental allergic encephalomyelitis in the Lewis rat, by administration of an acylated synthetic peptide of myelin basic protein.
    St Louis J; Chan EL; Singh B; Strejan GH
    J Neuroimmunol; 1997 Mar; 73(1-2):90-100. PubMed ID: 9058764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4.
    Xu LY; Huang YM; Yang JS; Van Der Meide PH; Link H; Xiao BG
    Clin Exp Immunol; 2000 Jun; 120(3):526-31. PubMed ID: 10844533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptic MBP epitope 1-20 is inducing autoimmune anterior uveitis without EAE in Lewis rats.
    Jiang S; Arendt A; Hargrave PA; Adamus G
    Cell Immunol; 2002; 217(1-2):87-94. PubMed ID: 12426004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99.
    Liu JQ; Bai XF; Shi FD; Xiao BG; Li HL; Levi M; Mustafa M; Wahren B; Link H
    Int Immunol; 1998 Aug; 10(8):1139-48. PubMed ID: 9723700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encephalitogenic regions for the Lewis rat within the myelin basic protein.
    Westall FC; Thompson M
    Immunol Commun; 1977; 6(1):13-21. PubMed ID: 67992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two minor determinants of myelin basic protein induce experimental allergic encephalomyelitis in SJL/J mice.
    Kono DH; Urban JL; Horvath SJ; Ando DG; Saavedra RA; Hood L
    J Exp Med; 1988 Jul; 168(1):213-27. PubMed ID: 2456367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent and convergent synthesis of polymannosylated dibranched antigenic peptide of the immunodominant epitope MBP(83-99).
    Friligou I; Rizzolo F; Nuti F; Tselios T; Evangelidou M; Emmanouil M; Karamita M; Matsoukas J; Chelli M; Rovero P; Papini AM
    Bioorg Med Chem; 2013 Nov; 21(21):6718-25. PubMed ID: 23993671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal cord neuropathology in rat experimental autoimmune encephalomyelitis: modulation by oral administration of myelin basic protein.
    Popovich PG; Yu JY; Whitacre CC
    J Neuropathol Exp Neurol; 1997 Dec; 56(12):1323-38. PubMed ID: 9413281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the antigen specificity and TCR repertoire, and TCR-based DNA vaccine therapy in myelin basic protein-induced autoimmune encephalomyelitis in DA rats.
    Miyakoshi A; Yoon WK; Jee Y; Matsumoto Y
    J Immunol; 2003 Jun; 170(12):6371-8. PubMed ID: 12794171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis.
    Aikawa Y; Tanuma N; Shin T; Makino S; Tanaka K; Matsumoto Y
    J Neuroimmunol; 1998 Aug; 89(1-2):35-42. PubMed ID: 9726823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.
    Fridkis-Hareli M; Santambrogio L; Stern JN; Fugger L; Brosnan C; Strominger JL
    J Clin Invest; 2002 Jun; 109(12):1635-43. PubMed ID: 12070311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.